CD8A and neoplasm: In the CheckMate-275 phase 2 clinical trial, 270 patients with platinum-resistant metastatic UC were treated with the anti-PD-1 antibody nivolumab; the presence of higher tumor infiltration by CD8+ T cells prior to treatment was associated with favorable PFS and OS after nivolumab treatment [33].